Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [Scientific article]Open Access
Lee Y.-M.; Cao K.; Leech M.; De Ponti F., Developing medical artificial intelligence leaders: International university consortium approach, «MEDICAL EDUCATION», 2021, 55, pp. 1321 - 1322 [Scientific article]
Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E., Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 740707 , pp. 1 - 11 [Scientific article]Open Access
Gatti M.; De Ponti F., Drug Interactions with Contraceptives, in: Trends in Andrology and Sexual Medicine, Berlino, Springer Science and Business Media Deutschland GmbH, 2021, pp. 325 - 359 (TRENDS IN ANDROLOGY AND SEXUAL MEDICINE) [Chapter or essay]
Gatti M.; De Ponti F., Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities, «PHARMACEUTICS», 2021, 13, Article number: 302 , pp. 1 - 23 [Scientific article]Open Access
Raschi E.; Antonazzo I.C.; Poluzzi E.; De Ponti F., Drug-induced systemic lupus erythematosus: Should immune checkpoint inhibitors be added to the evolving list?, «ANNALS OF THE RHEUMATIC DISEASES», 2021, 80, pp. 120 - 120 [Comment or similar]
Donker E.; Brinkman D.; Richir M.; Papaioannidou P.; Likic R.; Sanz E.J.; Christiaens T.; Costa J.; De Ponti F.; Gatti M.; Bottiger Y.; Kramers C.; Garner S.; Pandit R.; Van Agtmael M.; Tichelaar J., European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study, «BMJ OPEN», 2021, 11, Article number: e045635 , pp. 1 - 4 [Scientific article]Open Access
Bakkum, M. J.; Richir, M. C.; Papaioannidou, P.; Likic, R.; Sanz, E. J.; Christiaens, T.; Costa, J. N.; Maciulaitis, R.; Dima, L.; Coleman, J.; Tichelaar, J.; van Agtmael, M. A.; Atanasova, I.; Ganeva, M.; Gatchev, E.; Kostadinova, I. I.; Matanovic, S. M.; Vitezic, D.; Wozniak, G.; Kmonickova, E.; Urbanek, K.; Damkier, P.; Huupponen, R. K.; Auffret, M.; Bejan-Angoulvant, T.; Chouchana, L.; Cracowski, J. -L.; Drici, M. D.; Faillie, J. L.; Geniaux, H.; Molimard, M.; Orlikowski, D.; Palin, K.; Pers, Y. -M.; Picard, N.; Simon, N.; Toussirot, E.; Boger, R. H.; Cascorbi, I.; Mueller, S. C.; Regenthal, R.; Schwab, M.; Schwaninger, M. S.; Thuermann, P. A.; Wojnowski, L.; Kouvelas, D.; Riba, P.; Kerins, D. M.; Williams, D. J.; Cosentino, M.; De Ponti, F.; Filippelli, A.; Leone, R.; Locatelli, V.; Jansone, B.; Gulbinovic, R.; Mifsud, J.; Braszko, J. J.; Kocic, I.; Breitenfeld, L.; Castelo-Branco, M.; Conea, S.; Magyar, I.; Bevc, S.; Krzan, M.; Bernal, M. L.; Capella, D.; Carcas, A.; De Abajo, F, EurOP2E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 77, pp. 1209 - 1218 [Scientific article]Open Access
Gatti M.; Raschi E.; De Ponti F., Fluoroquinolones and Aortic Disease, «JAMA INTERNAL MEDICINE», 2021, 181, pp. 880 - 881 [Scientific article]
Bakkum M.J.; Tichelaar J.; Papaioannidou P.; Likic R.; Sanz Alvarez E.J.; Christiaens T.; Costa J.N.; Maciulaitis R.; Dima L.; Coleman J.; Richir M.C.; van Agtmael M.A.; Atanasova I.; Ganeva M.; Gatchev E.; Kostadinova I.I.; Mimica Matanovic S.; Vitezic D.; Greta W.; Kmonickova E.; Karel U.; Damkier P.; Huupponen R.K.; Auffret M.; Bejan-Angoulvant T.; Laurent C.; Jean-Luc C.; Drici M.D.; Faillie J.L.; Helene G.; Molimard M.; Orlikowski D.; Palin K.; Pers Y.-M.; Picard N.; Simon N.; Toussirot E.; Boger R.H.; Cascorbi I.; Mueller S.C.; Regenthal R.; Schwab M.; Schwaninger M.S.; Thuermann P.A.; Wojnowski L.; Kouvelas D.; Riba P.; Kerins D.M.; Williams D.J.; Cosentino M.; De Ponti F.; Filippelli A.; Leone R.; Locatelli V.; Jansone B.; Gulbinovic R.; Mifsud J.; Braszko Jan J.; Kocic I.; Luiza B.; Castelo-Branco M.; Simona C.; Ioan M.; Bevc S.; Mojca K.; Bernal M.L.; Capella D.; Carcas A.; De Abajo F.J.; Lopez-Rico M.; Lucena M.I.; Pontes C.; Bottiger Y.; Le Greves M.; de Waard-Siebinga I.;, Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 87, pp. 1001 - 1011 [Scientific article]Open Access
Gatti M.; Raschi E.; De Ponti F., Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis, «EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES», 2021, 40, pp. 1169 - 1176 [Scientific article]Open Access
Gatti M.; Fusaroli M.; Raschi E.; Moretti U.; Poluzzi E.; De Ponti F., Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system, «EXPERT OPINION ON DRUG SAFETY», 2021, 20, pp. 1421 - 1431 [Scientific article]
Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E., Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 87, pp. 1533 - 1540 [Scientific article]Open Access
Gatti M.; Raschi E.; De Ponti F., Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis, «EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY», 2021, 77, pp. 233 - 239 [Scientific article]Open Access
Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F., SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?, «EXPERT OPINION ON PHARMACOTHERAPY», 2021, 22, pp. 647 - 650 [Scientific article]